Medical Diagnostics: 9% Growth Projected for 2025

Diagnostic Medical Systems (DMS Group) achieved revenues of €50.0 million in 2025, representing organic growth of 9%. This growth was driven by a strong final quarter with a 17% increase, fueled by international expansion, particularly in North America. The Radiology and Bone Densitometry divisions recorded increases of 9% and 8%, respectively. The North American market, with 71% growth, proved to be the most successful, supported by OEM deliveries and strategic partnerships.

In parallel, the bone densitometry sector showed strong momentum at the end of the year. Despite logistical challenges, DMS Group maintained a balanced distribution between private label and OEM sales. With promising growth prospects for 2026, the group anticipates new deliveries and entry into new markets. Market pressures have not hindered the group's commitment to its strategic objectives for 2027.